Wegovy reaches peak levels in your body within one to three days – although this can vary from person to person.
Its long half-life of seven days means weekly injections are sufficient to produce significant effects, helping you lose weight efficiently.

Last updated on Nov 21, 2025.
Summary:
- Wegovy peaks in your body 2–3 days after injection for most people.
- Levels stay steady until day 7, when it begins to decline.
- Weekly doses help keep a stable level from week 5 onward.
- It usually takes up to 7 weeks for Wegovy to fully leave your system.
In short, Wegovy levels steadily rise, reaching peak concentration by day two or three. After this, the levels stay relatively stable and gradually decline after day seven.
Figure 1 – The absorption rate of semaglutide was measured for a 1mg/ml concentration. Please note that slight variations may occur with different dosage strengths.
Data taken from: Lau, D. C. W., Batterham, R. L., & le Roux, C. W. (2022). Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Expert Review of Clinical Pharmacology, 15(3), 251–268.
After injection, semaglutide is absorbed slowly into your bloodstream.
You won’t feel any effects on this day, as only a small amount may have been absorbed. This usually isn’t enough to produce a noticeable effect.
The levels of semaglutide will steadily increase in the bloodstream and travel to the target organs, such as the brain.
You’ll slowly start to feel its effects, like feeling fuller, but this won’t be to its full extent.
Semaglutide reaches peak concentration, with approximately 89% being absorbed. This is the point with the highest level of semaglutide circulating at any given time.
You’ll begin to notice a change in your appetite, often feeling fuller and less hungry.
You may also get side effects like nausea, vomiting, diarrhea, and headaches. Although not everyone gets them, they are completely normal and show that semaglutide is working.
Semaglutide levels will decline slowly until day seven and continue to decrease afterwards.
On day seven, you’ll take another dose to maintain the high levels. As you continue taking weekly doses, a steady state will be achieved by week five, meaning the levels remain consistent until you stop treatment.
Most people will reach peak Wegovy levels by day three, although it may take longer for some people.
The site of injection (thigh, upper arm or abdomen) doesn’t matter when injecting Wegovy, as all three sites have a similar rate of absorption. However, injecting at the most fatty part of each area can improve absorption rate.
It’s also important to rotate injection sites weekly to prevent irritation, pain and discomfort.
Different weight loss drugs contain different active ingredients, so the rate of absorption for each medication will differ.
Liraglutide (the active ingredient in Saxenda) has a quicker absorption rate than Wegovy and peaks at around 11 hours. But this doesn’t make it more effective, according to research. Liraglutide is also more quickly eliminated from the body, which may make it inconvenient, as you would have to inject daily at consistent times to reach stable levels.
Zepbound reaches peak concentrations at a similar time to Wegovy in approximately one to three days, and reaches a steady level by week four.
Sourcing guidelines:
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Expert Review of Clinical Pharmacology, 15(3), 251–268.
Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk.
Once-Weekly Semaglutide for Weight Management: A Clinical Review. The Journal of Pharmacy Technology : JPT : Official Publication of the Association of Pharmacy Technicians, 38(4), 239.
Saxenda 6 mg/mL solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk.
Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: A systematic review and meta-analysis. Frontiers in Pharmacology, 16, 1438318.
Mounjaro KwikPen 10mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk.
Have a subject you’d like us to cover in a future article? Let us know.
We're making healthcare more about you. Sign up to our newsletter for personalized health articles that make a difference.
Disclaimer: The information provided on this page is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about your health, please talk to a doctor.
Authorised and Regulated by:
We couldn't find what you're looking for.
Here's everything we treat. Or, if you're looking for something we don't have yet, you can suggest something.
(And leave your email too, so we can let you know if we write an article based on your suggestion.)
By clicking 'Subscribe now' you're agreeing to our Privacy Policy.
Last updated on Nov 21, 2025.
Our experts continually monitor new findings in health and medicine, and we update our articles when new info becomes available.
Nov 21, 2025
Published by: The Treated Content Team. Medically reviewed by: Dr Alexandra Cristina Cowell, Writer & Clinical Content ReviewerHow we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.